Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 9/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 9/20 | 0.41 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.36 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580548 | 0.85 | CA1 (0.46) | CA1CA2GAACA12CA3 | |
| SCHEMBL3580492 | 0.85 | GAA (0.52) | CA1CA2GAACA12CA7 | |
| SCHEMBL3586172 | 0.78 | CYP19A1 (0.41) | CA1CA2GAAKDM4EALDH1A1 | |
| SCHEMBL3587585 | 0.77 | ALPL (0.36) | CA1CA2GAACA12CA3 | |
| SCHEMBL14185173 | 0.77 | GAA (0.51) | CA1CA2GAACA12CA9 | |
| SCHEMBL3589304 | 0.77 | GAA (0.37) | CA1CA2GAACA12CA3 | |
| SCHEMBL3589603 | 0.76 | GAA (0.45) | CA1CA2GAACA12CA3 | |
| SCHEMBL14185172 | 0.76 | GAA (0.49) | CA1CA2GAACA12CA9 | |
| SCHEMBL3584054 | 0.75 | CA1 (0.45) | CA1CA2GAACA12CA3 | |
| SCHEMBL14185181 | 0.75 | GAA (0.48) | GAACA12CA9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | CA1 2466/4885CA2 628/4885CA12 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.